Phase I study of OBI-888 in patients with locally advanced or metastatic solid tumors of all types.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2018
At a glance
- Drugs OBI 888 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 18 Jan 2018 New trial record
- 17 Jan 2018 According to the OBI Pharma media release, company announced that U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a Phase 1 study of OBI-888.